Cliramitug is a monoclonal antibody that targets human transthyretin protein (TTR). By binding to TTR, Cliramitug inhibits its amyloid formation process and exhibits activity that prevents amyloid deposition. Cliramitug holds potential for research in transthyretin amyloidosis-related diseases, including certain neurological and cardiovascular conditions.